Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Financings Routine −

ME Therapeutics Announces Private Placement

ME Therapeutics raises $500K via private placement to fund R&D and pursue U.S. listing as stock trades near 52-week lows.

By The Northwire Desk — AI Analysis Jun 03, 2026 · 15:13 METX · 1.99 ME Therapeutics Holdings Inc.
Executive Summary
  • ME Therapeutics announced a non-brokered private placement to raise gross proceeds of up to $500,000, with an option to upsize to $1,000,000.
  • The offering is priced at $1.70 per unit, comprising one common share and one non-transferrable warrant exercisable at $2.00 for three years.
  • Proceeds are earmarked for R&D advancement, evaluating strategic transactions, pursuing a U.S. listing, marketing, investor relations, and working capital.
  • Shares and warrants carry a four-month-and-one-day hold period. Insider participation is expected.
  • This follows a series of routine scientific updates: a U.S. patent grant for a G-CSF antibody candidate (Sept 2025), a license for a CD22 nanobody asset from the NRC (Oct 2025), and a preclinical update on in vivo CAR and STING mRNA programs (April 2026).
Material Impact
  • The financing is dilutive and priced at a discount to the recent market price of $1.99, signaling management's need for immediate liquidity and potentially reflecting a lack of premium valuation support from the market.
  • The capital raise is modest relative to typical biotech burn rates, indicating a short-term runway extension rather than a transformative capital event.
  • The use of proceeds highlights a strategic pivot toward a U.S. listing, which may improve liquidity and access to larger capital markets, but execution risk remains high.
  • No material change to the scientific pipeline or regulatory milestones is introduced; the news is purely capital-focused.
METX · Price
Company Overview
  • ME Therapeutics is a preclinical-stage biotechnology company focused on immuno-oncology.
  • Flagship programs include an in vivo dual CD19/CD22-targeted CAR candidate and a therapeutic mRNA candidate targeting the STING pathway for solid tumors.
  • The company also holds a U.S. patent for a G-CSF antibody candidate (H1B11-12) and has licensed a CD22 nanobody from the National Research Council of Canada.
  • All programs are in preclinical or early discovery stages, with no clinical data to date.
Read the original news release →

More from ME Therapeutics Holdings Inc.

Apr 29, 2026 · 09:00

ME Therapeutics Advances mRNA Pipeline Amidst Price Consolidation at $2.50 Support Level

Other Jan 30, 2026 · 16:26

ME Therapeutics talks pipeline and in vivo CAR plans

Other Jan 28, 2026 · 14:39

SEDAR Interim Financial Statements

None Oct 16, 2025 · 18:53

ME Therapeutics licenses NRC's CD22 nanobody asset

M&A / Property Oct 16, 2025 · 09:00

ME Therapeutics Granted Licence for CD22 Nanobody Asset to Expand Next-Gen In Vivo CAR Cell Therapy Program

M&A / Property Sep 26, 2025 · 17:04

ME obtains U.S. patent for G-CSF antibody candidate

M&A / Property